Abstract 1511P
Background
Gemcitabine-based adjuvant chemotherapy (aGC) is a therapeutic mainstay after surgery for pancreatic ductal adenocarcinoma (PDAC), but relevant efficacy predictors are still lacking. Intratumoral gram-negative bacteria can suppress response to aGC. We assessed the effect of intratumoral bacterial colonization on aGC-efficacy and examined whether peri-operative antibiotic treatment (ABT) improved patient outcome.
Methods
Intratumoral bacteria were detected by immunohistochemistry (IHC) for lipopolysaccharide (gram-negative) and lipoteichoic acid (gram-positive) in the samples of 342 resected PDAC patients treated with either aGC or none / non-gemcitabine-based adjuvant chemotherapy (naGC). Preoperative ABT was defined as ABT for more than 24 hours within 30 days before resection. Postoperative ABT was defined as ABT for more than 24 hours within 30 days after resection. Data of 177 patients from the TCGA database were used for validation.
Results
High bacterial colonization (bacHI) conferred worse disease-free survival (DFS, 9.4 vs 19.1 months, p<0.001) and overall survival (OS, 19.4 months vs 34.0 months, p<0.001) in aGC patients, but made no statistical difference in naGC patients (p=0.66 and p=0.42). BacHI did not correlate with the tumors transcriptional subtype, pre-operative ATB, bile duct interventions or other prognostic clinicopathological variables. Pre-operative ABT did not affect patient outcome, irrespective of adjuvant chemotherapy. Post-operative ABT significantly improved patientś DFS (17.5 vs. 10.8 months, p<0.001) and OS (37.8 vs. 20.6 months, p<0.001) in the aGC cohort, but not in the naGC cohort (p=0.60 and p=0.97). The findings were confirmed by inverse propensity score weighted multivariable Cox regression analyses and in the external validation cohort.
Conclusions
High intratumoral bacterial abundance is a negative predictor of adjuvant gemcitabine efficacy in PDAC but can be overcome by post-operative antibiotic treatment prior adjuvant therapy. Detection of intratumoral bacteria in resection specimens by IHC may guide the use of antibiotics to improve therapy response and patient outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1515P - Surgery versus chemotherapy for pulmonary oligometastasis after pancreatectomy: A multicentre observational study
Presenter: Ryoji Takada
Session: Poster session 18
1516P - Lung-only metastatic PDAC: Another disease?
Presenter: Léa Mercier
Session: Poster session 18
1517P - Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study
Presenter: Giulia Orsi
Session: Poster session 18
1518P - Stereotactic radiotherapy and IMM-101 in patients with oligometastatic pancreatic cancer following FOLFIRINOX: The MEPANC trial
Presenter: Leonoor Wismans
Session: Poster session 18
Resources:
Abstract
1519P - Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study
Presenter: Makoto Ueno
Session: Poster session 18
1520P - Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis
Presenter: Andreas Reichinger
Session: Poster session 18
Resources:
Abstract
1521P - Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study
Presenter: Hiroshi Imaoka
Session: Poster session 18
1522P - S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P)
Presenter: Yuichiro Tozuka
Session: Poster session 18
1523P - Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
Presenter: Yasin Sezgin
Session: Poster session 18